Seres Therapeutics Inc
MCRB14.695USD
+0.705+5.04%
Horário de mercado （ET）Cotações atrasadas em 15 min
6.42MValor de mercado
0.09P/L TTM
Mais detalhes de Seres Therapeutics Inc Empresa
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. The Company is engaged in developing SER-155, which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a clinical study in patients undergoing allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). The Company is also advancing additional cultivated oral live biotherapeutics for medically vulnerable populations, including those with chronic liver disease, cancer neutropenia, and solid organ transplants. The Company's clinical and nonclinical data across its programs support the development of live biotherapeutics to target the prevention and treatment of a broad swath of infections, and in inflammatory and immune diseases.
Informações da empresa
Código da empresaMCRB
Nome da EmpresaSeres Therapeutics Inc
Data de listagemJun 26, 2015
CEOMr. Thomas J. DesRosier, J.D.
Número de funcionários103
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 26
Endereço101 Cambridge Park Drive
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02140
Telefone16179459626
Sitehttps://www.serestherapeutics.com/
Código da empresaMCRB
Data de listagemJun 26, 2015
CEOMr. Thomas J. DesRosier, J.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Thomas J. DesRosier, J.D.
Mr. Thomas J. DesRosier, J.D.
Co-President, Co-Chief Executive Officer, Chief Legal Officer, Secretary
Co-President, Co-Chief Executive Officer, Chief Legal Officer, Secretary
7.29K
+2.32%
Dr. Matthew R. Henn, Ph.D.
Dr. Matthew R. Henn, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
4.38K
+3.81%
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
3.17K
--
Dr. Teresa L. Young, Ph.D.
Dr. Teresa L. Young, Ph.D.
Executive Vice President, Chief Commercial and Strategy Officer
Executive Vice President, Chief Commercial and Strategy Officer
--
--
Mr. Paul R. Biondi
Mr. Paul R. Biondi
Independent Director
Independent Director
--
--
Mr. Stephen A. Berenson
Mr. Stephen A. Berenson
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
--
--
Dr. Claire M. Fraser, Ph.D.
Dr. Claire M. Fraser, Ph.D.
Independent Director
Independent Director
--
--
Dr. Hans-Juergen Woerle, M.D., Ph.D.
Dr. Hans-Juergen Woerle, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Marella Thorell
Ms. Marella Thorell
Co-President, Co-Chief Executive Officer, Chief Financial Officer
Co-President, Co-Chief Executive Officer, Chief Financial Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Thomas J. DesRosier, J.D.
Mr. Thomas J. DesRosier, J.D.
Co-President, Co-Chief Executive Officer, Chief Legal Officer, Secretary
Co-President, Co-Chief Executive Officer, Chief Legal Officer, Secretary
7.29K
+2.32%
Dr. Matthew R. Henn, Ph.D.
Dr. Matthew R. Henn, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
4.38K
+3.81%
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
3.17K
--
Dr. Teresa L. Young, Ph.D.
Dr. Teresa L. Young, Ph.D.
Executive Vice President, Chief Commercial and Strategy Officer
Executive Vice President, Chief Commercial and Strategy Officer
--
--
Mr. Paul R. Biondi
Mr. Paul R. Biondi
Independent Director
Independent Director
--
--
Mr. Stephen A. Berenson
Mr. Stephen A. Berenson
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Detalhamento da receita
FY2023
FY2022
FY2021
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
126.33M
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Flagship Ventures
13.24%
Fidelity Management & Research Company LLC
12.51%
Nestle SA
12.47%
The Vanguard Group, Inc.
3.49%
BlackRock Institutional Trust Company, N.A.
0.96%
Other
57.33%
Investidores
Investidores
Proporção
Flagship Ventures
13.24%
Fidelity Management & Research Company LLC
12.51%
Nestle SA
12.47%
The Vanguard Group, Inc.
3.49%
BlackRock Institutional Trust Company, N.A.
0.96%
Other
57.33%
Tipos de investidores
Investidores
Proporção
Investment Advisor
19.23%
Venture Capital
13.24%
Corporation
12.47%
Investment Advisor/Hedge Fund
1.46%
Research Firm
1.04%
Individual Investor
0.59%
Hedge Fund
0.45%
Bank and Trust
0.05%
Other
51.47%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
284
4.24M
48.53%
-1.00M
2025Q1
303
4.22M
48.29%
-1.11M
2024Q4
311
85.93M
50.33%
-20.68M
2024Q3
330
86.09M
50.57%
-26.54M
2024Q2
336
69.70M
45.95%
-51.91M
2024Q1
345
94.53M
65.81%
-35.72M
2023Q4
345
98.23M
75.49%
-30.72M
2023Q3
356
117.05M
93.47%
-19.47M
2023Q2
384
121.97M
97.71%
-18.66M
2023Q1
378
115.00M
93.33%
-29.90M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Flagship Ventures
1.16M
13.24%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
1.09M
12.51%
+2.16K
+0.20%
Mar 31, 2025
Nestle SA
1.09M
12.47%
+709.39K
+186.83%
Sep 30, 2024
The Vanguard Group, Inc.
304.60K
3.49%
+10.91K
+3.71%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
84.10K
0.96%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
80.94K
0.93%
+5.42K
+7.17%
Mar 31, 2025
Bank Vontobel AG
54.30K
0.62%
+7.38K
+15.74%
Mar 31, 2025
UBS Financial Services, Inc.
69.22K
0.79%
+52.11K
+304.43%
Mar 31, 2025
Charles Schwab Investment Management, Inc.
41.70K
0.48%
-1.59K
-3.66%
Mar 31, 2025
Susquehanna International Group, LLP
35.86K
0.41%
+19.47K
+118.77%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Micro-Cap ETF
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0%
Direxion Daily S&P Biotech Bull 3X Shares
0%
iShares Russell 2000 Growth ETF
0%
iShares Biotechnology ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
FlexShares Morningstar US Market Factor Tilt Index Fund
0%
Proshares Ultra Russell 2000
0%
Ver Mais
iShares Micro-Cap ETF
Proporção0.01%
Invesco RAFI US 1500 Small-Mid ETF
Proporção0%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0%
iShares Russell 2000 Growth ETF
Proporção0%
iShares Biotechnology ETF
Proporção0%
Invesco Nasdaq Biotechnology ETF
Proporção0%
ProShares Hedge Replication ETF
Proporção0%
iShares Russell 2000 ETF
Proporção0%
FlexShares Morningstar US Market Factor Tilt Index Fund
Proporção0%
Proshares Ultra Russell 2000
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
